证券代码：000598 证券简称：兴蓉环境 成都市兴蓉环境股份有限公司 2026 年 1 月 9 日投资者关系活动记录表 编号：2026-01 答：截至目前，公司运营及在建的供水项目规模约 430 万吨/日、 污水处理项目规模逾 480 万吨/日、垃圾焚烧发电项目规模为 12,000 吨/日。公司在建的污水处理项目中，成都市第五净水厂（二 期）项目主体施工及主要设备安装已完成，正逐步开展设备调试 工作，成都市第八净水厂（二期）项目、成都合作污水处理厂（四 期）项目已进入调试阶段，成都市第六净水厂（二期）项目进入 试运行并积极推进建设收尾工作。成都万兴环保发电厂（三期） 正在有序推进项目建设，逐步开展各机组系统调试，系统调试合 格且稳定运行后可并网发电，项目整体预计今年投运。 问题 3：关于公司供排水业务价格的调整机制。 答：公司供水业务价格根据国家政策规定和相关特许权协议约定， 在满足相关调价原则的情况下可向政府价格行政主管部门提交水 价调整申请。供水价格的调整须经成本监审、听证会等程序通过 后执行。如遇国家或省对上游资源水价、水利工程水价开征或调 整时实行同步同幅联动调整。公司污水处理服务费单价按照与相 关 ...

Core Viewpoint - The resurgence of dividend-type critical illness insurance is anticipated in the market, driven by recent policy support from the National Financial Regulatory Administration [1][3][4] Policy Support - The National Financial Regulatory Administration's guidance encourages insurance companies with good regulatory ratings to develop dividend-type long-term health insurance products [3][4] - Major insurers like China Ping An and Xinhua Insurance have expressed their commitment to research and develop dividend-type critical illness insurance products in response to the new policy [5][6] Market Dynamics - The traditional critical illness insurance market has faced challenges, leading to a renewed interest in dividend-type products as a potential solution [4][7] - The introduction of dividend mechanisms is seen as a way to enhance the attractiveness of long-term health insurance products and innovate their offerings [5][6] Product Concerns - There is a distinction between genuine dividend-type critical illness insurance and products that are merely labeled as such, with the latter often being criticized as "pseudo-dividend critical illness insurance" [6] - True dividend-type critical illness insurance should link dividends directly to the performance of the critical illness insurance itself, rather than relying on the performance of a separate dividend insurance component [6] Industry Challenges - The insurance industry faces significant hurdles in reintroducing dividend-type critical illness insurance, including the need for accurate pricing, stable investment returns, and strict underwriting practices [8] - Insurers must navigate complex financial considerations, including capital requirements and customer expectations, to successfully launch these products [8][9] Consumer Acceptance - Gaining consumer trust and acceptance of dividend-type critical illness insurance will be crucial for its long-term success in the market [9]

Group 1 - The core viewpoint of the article highlights the recent research conducted by Silver Leaf Investment on Huafeng Chemical, revealing a decline in revenue and net profit for the first half of 2025 [1] - Huafeng Chemical reported a revenue of 12.137 billion yuan, a year-on-year decrease of 11.7%, and a net profit decline of 35.23% [1] - The company advocates for "anti-involution" in the spandex industry, focusing on differentiated competition, industry chain collaboration, and technological innovation to enhance competitiveness [1] Group 2 - The industry inventory stands at 50 days, while Huafeng Chemical's inventory is at 20 days, indicating intensified industry reshuffling and increased concentration as small capacities exit the market [1] - Huafeng Chemical maintains strong customer loyalty due to product quality and technological advantages, with its spandex segment operating at full capacity [1] - The company anticipates completing its asset restructuring by December 2026, with only 1% of sales directed to the U.S. market [1] Group 3 - Huafeng Chemical is collaborating with Eastman to produce acetic acid, with the current investment scale being small and not significantly impacting the company's performance [1] - There are no new expansion plans, and the differentiated spandex production capacity of 150,000 tons per year is expected to reach full production by the end of 2026 [1] - The new production capacity has a low investment per ton and features more economical, environmentally friendly, and efficient processes [1] Group 4 - The company will continue to improve its dividend system, implementing a reasonable, sustainable, and stable dividend distribution policy [1]

Group 1 - Three new floating rate funds were launched on August 4, including E Fund Value Return Mixed, China Europe Core Smart Mixed, and CCB Medical Innovation Stock, with fundraising periods ending on August 20, August 15, and August 22 respectively [2][3] - The issuance scale for CCB Medical Innovation Stock is capped at 3 billion yuan [3] - The new floating rate funds feature differentiated performance benchmarks, which will influence the fee rates based on the funds' performance relative to these benchmarks [1][4] Group 2 - The performance benchmark for China Europe Core Smart Mixed is set as: 80% of the CSI 800 Index return + 5% of the CSI Hong Kong Stock Connect Composite Index (RMB) return + 15% of the China Bond Composite Index return [4] - E Fund Value Return Mixed has a performance benchmark of: 55% of the CSI 800 Index return + 20% of the CSI Hong Kong Stock Connect Composite Index return + 25% of the China Bond Total Index return [4] - CCB Medical Innovation Stock's performance benchmark is: 70% of the CSI Medical and Health Index return + 15% of the China Bond Composite Index return + 15% of the Hang Seng Healthcare Index return [4] Group 3 - The funds are designed to invest in both A-shares and Hong Kong stocks, with a maximum of 50% of stock assets allocated to Hong Kong Stock Connect stocks [3] - The management fee structure includes three tiers: 1.2% for the benchmark tier, 1.5% for the upgrade tier, and 0.6% for the downgrade tier, based on the fund's performance after one year [5] - The funds aim to enhance the holding experience through a quarterly dividend mechanism, with China Europe Core Smart Mixed implementing a "performance-based quarterly dividend" clause [1][3]